Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4966 AL 4980

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability

Lim YY, Maruff P, Getter C, Snyder PJ.

Alzheimers Dement. 2016 Apr;12(4):454-8. doi: 10.1016/j.jalz.2015.09.005. Epub 2015 Dec 30.

Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine

Blautzik J, Keeser D, Paolini M, Kirsch V, Berman A, Coates U, Reiser M, Teipel SJ, Meindl T.

Eur Neuropsychopharmacol. 2016 Mar;26(3):602-13. doi: 10.1016/j.euroneuro.2015.12.006. Epub 2015 Dec 10.

The APOE genotype: modification of therapeutic responses in Alzheimer's disease

Hanson AJ, Craft S, Banks WA.

Curr Pharm Des. 2015;21(1):114-20. doi: 10.2174/1381612820666141020164222.

Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia

Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S.

J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791.

Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms

Babiloni C, Lizio R, Marzano N, Capotosto P, Soricelli A, Triggiani AI, Cordone S, Gesualdo L, Del Percio C.

Int J Psychophysiol. 2016 May;103:88-102. doi: 10.1016/j.ijpsycho.2015.02.008. Epub 2015 Feb 7.

Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression?

Safouris A, Psaltopoulou T, Sergentanis TN, Boutati E, Kapaki E, Tsivgoulis G.

CNS Neurol Disord Drug Targets. 2015;14(2):257-69. doi: 10.2174/1871527314666150217123147.

The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model

Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM.

Behav Brain Res. 2015;287:96-9. doi: 10.1016/j.bbr.2015.03.029. Epub 2015 Mar 20.

Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials

Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N.

Int J Neuropsychopharmacol. 2015 Jun 19;18(12):pyv070. doi: 10.1093/ijnp/pyv070.

Advancements in the treatment of agitation in Alzheimer's disease

Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP.

Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422.

Role of RAGE in Alzheimer's Disease

Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, Chang L, Yan LJ, Zhao B.

Cell Mol Neurobiol. 2016 May;36(4):483-95. doi: 10.1007/s10571-015-0233-3. Epub 2015 Jul 15.

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Geriatr Psychiatry. 2015 Nov;23(11):1127-33. doi: 10.1016/j.jagp.2015.05.006. Epub 2015 May 19.

EFFECT OF EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID SUPPLEMENTATIONS TO CONTROL COGNITIVE DECLINE IN DEMENTIA AND ALZHEIMER'S DISEASE: A SYSTEMATIC REVIEW

de Souza Fernandes DP, Canaan Rezende FA, Pereira Rocha G, De Santis Filgueiras M, Silva Moreira PR, Gonçalves Alfenas Rde C.

Nutr Hosp. 2015 Aug 1;32(2):528-33. doi: 10.3305/nh.2015.32.2.9111.

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease

Liu CS, Chau SA, Ruthirakuhan M, Lanctôt KL, Herrmann N.

CNS Drugs. 2015 Aug;29(8):615-23. doi: 10.1007/s40263-015-0270-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias